Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and FLT3-ITD results

Patient number	Age/sex	Induction therapy	ITD mutation by CE-PCR at diagnosis		ITD mutation by MRD assay at diagnosis		ITD mutation by MRD assay at remission		Clinical outcome
Patient number	Age/sex	Induction therapy	Length, bp	VAF, %	Length, bp	VAF	Length, bp	VAF	Clinical outcome
1	59/F	AcIVP16	51	5	51	7.7	51	0.0017	Alive, disease free 5 y after diagnosis
1	59/F	AcIVP16	30	5	30	1.42	30 (ND)	0	Alive, disease free 5 y after diagnosis
2	56/F	AcIVP16	51	37	51	47.48	51	0.0027	Alive, disease free 5 y after diagnosis
3	64/M	AcIVP16	81	46	81	75.69	81	0.020	Alive, disease free 3 y after diagnosis
4	67/M	7 + 3 + gilteritinib	21	5	21	3.93, 0.16	None detected	0	Alive, disease free 1 y after diagnosis
4	67/M	7 + 3 + gilteritinib	21	5	60	3.93, 0.16	None detected	0	Alive, disease free 1 y after diagnosis
5	67/F	AcIVP16	18	9	18	11.09	18	0.0077	Alive, disease free 4 y after diagnosis
					30	0.10	30 (ND)	0
					39	0.35	39 (ND)	0
6	56/M	7 + 3 + gilteritinib	51	81	51	85.77	51	0.06	Alive, disease free 2.5 y after diagnosis
7	52/M	AcIVP16	27	5	24	0.57	24	0.2	Relapsed with the 42-bp ITD, died of relapsed disease 2 y after diagnosis
			42	<5	27	5.68	27	0.099
			93	<5	42	0.75	42	0.1
			96	<5	63	0.20	63	0.22
					93	7.02	93 (ND)	0
					96	11.45	96	0.013
8	31/F	7 + 3 + midostaurin	15	45	15	45.27	15	0.004	Alive, disease free 2 y after diagnosis
9	72/F	7 + 3 + midostaurin	33	5	33	6.48, 0.32	33	0.005	Alive, disease free 2 y after diagnosis
9	72/F	7 + 3 + midostaurin	33	5	69	6.48, 0.32	69 (ND)	0	Alive, disease free 2 y after diagnosis
10	68/F	7 + 3	24	37	24	39.53	24	0.018	Alive, disease free 4 y after diagnosis
11	57/F	AcIVP16	15	45	15	44.39	15	0.04	Relapsed with the 15-bp ITD and died 1 y after diagnosis
12	43/M	7 + 3 + midostaurin	60	30	60	38.36	60	0.008	Alive, disease free 2 y after diagnosis
13	67/F	7 + 3 + gilteritinib	27	10	27	25.52, 1.87	27	0.003	On gilteritinib maintenance after transplant, relapsed with AML lacking ITD
13	67/F	7 + 3 + gilteritinib	27	10	108	25.52, 1.87	108 (ND)	0
14	47/M	7 + 3 + sorafenib	72	4	72	30.97	72	0.005	Died of GVHD 19 mo after diagnosis
15	68/F	7 + 3	45	31	45	46.7	45	2.17	Alive, disease free 4 y after diagnosis
16	60/M	7 + 3 + gilteritinib	24	36	24	37.63	24	0.004	Alive, disease free 2 y after diagnosis
17	44/F	AcIVP16	48	72	48	70.37	48	0.031	Alive, disease free 5 y after diagnosis

Patient number	Age/sex	Induction therapy	ITD mutation by CE-PCR at diagnosis		ITD mutation by MRD assay at diagnosis		ITD mutation by MRD assay at remission		Clinical outcome
Patient number	Age/sex	Induction therapy	Length, bp	VAF, %	Length, bp	VAF	Length, bp	VAF	Clinical outcome
1	59/F	AcIVP16	51	5	51	7.7	51	0.0017	Alive, disease free 5 y after diagnosis
1	59/F	AcIVP16	30	5	30	1.42	30 (ND)	0	Alive, disease free 5 y after diagnosis
2	56/F	AcIVP16	51	37	51	47.48	51	0.0027	Alive, disease free 5 y after diagnosis
3	64/M	AcIVP16	81	46	81	75.69	81	0.020	Alive, disease free 3 y after diagnosis
4	67/M	7 + 3 + gilteritinib	21	5	21	3.93, 0.16	None detected	0	Alive, disease free 1 y after diagnosis
4	67/M	7 + 3 + gilteritinib	21	5	60	3.93, 0.16	None detected	0	Alive, disease free 1 y after diagnosis
5	67/F	AcIVP16	18	9	18	11.09	18	0.0077	Alive, disease free 4 y after diagnosis
					30	0.10	30 (ND)	0
					39	0.35	39 (ND)	0
6	56/M	7 + 3 + gilteritinib	51	81	51	85.77	51	0.06	Alive, disease free 2.5 y after diagnosis
7	52/M	AcIVP16	27	5	24	0.57	24	0.2	Relapsed with the 42-bp ITD, died of relapsed disease 2 y after diagnosis
			42	<5	27	5.68	27	0.099
			93	<5	42	0.75	42	0.1
			96	<5	63	0.20	63	0.22
					93	7.02	93 (ND)	0
					96	11.45	96	0.013
8	31/F	7 + 3 + midostaurin	15	45	15	45.27	15	0.004	Alive, disease free 2 y after diagnosis
9	72/F	7 + 3 + midostaurin	33	5	33	6.48, 0.32	33	0.005	Alive, disease free 2 y after diagnosis
9	72/F	7 + 3 + midostaurin	33	5	69	6.48, 0.32	69 (ND)	0	Alive, disease free 2 y after diagnosis
10	68/F	7 + 3	24	37	24	39.53	24	0.018	Alive, disease free 4 y after diagnosis
11	57/F	AcIVP16	15	45	15	44.39	15	0.04	Relapsed with the 15-bp ITD and died 1 y after diagnosis
12	43/M	7 + 3 + midostaurin	60	30	60	38.36	60	0.008	Alive, disease free 2 y after diagnosis
13	67/F	7 + 3 + gilteritinib	27	10	27	25.52, 1.87	27	0.003	On gilteritinib maintenance after transplant, relapsed with AML lacking ITD
13	67/F	7 + 3 + gilteritinib	27	10	108	25.52, 1.87	108 (ND)	0
14	47/M	7 + 3 + sorafenib	72	4	72	30.97	72	0.005	Died of GVHD 19 mo after diagnosis
15	68/F	7 + 3	45	31	45	46.7	45	2.17	Alive, disease free 4 y after diagnosis
16	60/M	7 + 3 + gilteritinib	24	36	24	37.63	24	0.004	Alive, disease free 2 y after diagnosis
17	44/F	AcIVP16	48	72	48	70.37	48	0.031	Alive, disease free 5 y after diagnosis

All 17 patients had normal/intermediate karyotype and NPM1 mutation at diagnosis. All 17 patients achieved complete remission after a single cycle of induction therapy, and all underwent allogeneic transplant in first remission. Chemotherapy regimens: AcIVP16 = Cytarabine 2000 mg/m² continuous infusion days 1 to 3, idarubicin 8 mg/m² per day on days 1 to 3, etoposide 400 mg/m² per day on days 8 to 10; 7 + 3 = cytarabine 100 to 200 mg/m² per day on days 1 to 7, idarubicin 12 mg/m² per day on days 1 to 3.

GVHD, graft-versus-host disease; ND, not detectable; VAF, variant allele frequency.

View Large

This Feature Is Available To Subscribers Only